After Lybalvi’s Solid Early Launch, Alkermes Touts Neuropsychiatry Potential

 
• By Joseph Haas
  
Schizophrenia
Alkermes is seeing promise in the early launch metrics for Lybalvi

More from Strategy

More from Business